KR20010012568A - 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 - Google Patents

펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR20010012568A
KR20010012568A KR1019997010523A KR19997010523A KR20010012568A KR 20010012568 A KR20010012568 A KR 20010012568A KR 1019997010523 A KR1019997010523 A KR 1019997010523A KR 19997010523 A KR19997010523 A KR 19997010523A KR 20010012568 A KR20010012568 A KR 20010012568A
Authority
KR
South Korea
Prior art keywords
parathyroid hormone
hormone analogs
peptide parathyroid
peptide
analogs
Prior art date
Application number
KR1019997010523A
Other languages
English (en)
Other versions
KR100351213B1 (ko
Inventor
콘돈스티븐엠
모리쯔이사벨
Original Assignee
오흘러 로스 제이.
아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오흘러 로스 제이., 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 filed Critical 오흘러 로스 제이.
Publication of KR20010012568A publication Critical patent/KR20010012568A/ko
Application granted granted Critical
Publication of KR100351213B1 publication Critical patent/KR100351213B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019997010523A 1997-05-14 1998-05-13 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물 KR100351213B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
US60/046,472 1997-05-14

Publications (2)

Publication Number Publication Date
KR20010012568A true KR20010012568A (ko) 2001-02-15
KR100351213B1 KR100351213B1 (ko) 2002-09-05

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997010523A KR100351213B1 (ko) 1997-05-14 1998-05-13 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물

Country Status (20)

Country Link
US (2) US6472505B1 (ko)
EP (1) EP0986395A4 (ko)
JP (1) JP2001517957A (ko)
KR (1) KR100351213B1 (ko)
CN (1) CN1261281A (ko)
AP (1) AP9901686A0 (ko)
AU (1) AU746461B2 (ko)
BG (1) BG103957A (ko)
BR (1) BR9808786A (ko)
CA (1) CA2290443A1 (ko)
EA (1) EA002819B1 (ko)
HU (1) HUP0003349A3 (ko)
IL (1) IL132901A0 (ko)
NO (1) NO995568L (ko)
OA (1) OA11216A (ko)
PL (1) PL336803A1 (ko)
SK (1) SK151599A3 (ko)
UA (1) UA62967C2 (ko)
WO (1) WO1998051324A1 (ko)
ZA (1) ZA984077B (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101629A2 (en) 1998-04-15 2003-03-28 Aventis Pharma Inc Process for the preparation of resin-bound cyclic peptides
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2003097690A2 (en) * 2002-05-16 2003-11-27 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
BRPI0412664A (pt) * 2003-07-15 2006-09-26 Ca Nat Research Council método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
CA2613619A1 (en) 2005-07-07 2007-01-18 Fulcrum Sp Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
DK2084183T3 (da) * 2006-10-13 2010-08-16 Lilly Co Eli Pegyleret PTH som PTH-receptormodulatorer og anvendelser deraf
EP2391377A2 (en) 2009-02-02 2011-12-07 Ramot at Tel-Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
CA2759201A1 (en) 2009-04-01 2010-10-07 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
EP2435078A1 (en) 2009-05-28 2012-04-04 Yeda Research and Development Co. Ltd. Methods of treating inflammation
SG10201406921SA (en) * 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
MX358161B (es) * 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012173694A1 (en) * 2011-06-17 2012-12-20 Fluidic, Inc. Ionic liquid containing sulfonate ions
EP2823040B1 (en) 2012-03-06 2018-08-01 Cellect Biotherapeutics Ltd. Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
EP3046929B1 (en) 2013-09-17 2019-01-16 Yeda Research and Development Co., Ltd. Erk-derived peptides and uses thereof
US20160340659A1 (en) 2014-01-30 2016-11-24 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
EP3261582B1 (en) 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
KR20190091192A (ko) 2016-12-01 2019-08-05 라모트 앳 텔-아비브 유니버시티 리미티드 신경 손상의 병용 치료제
CA3059022A1 (en) 2017-04-07 2018-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Hair care compositions
WO2018216011A1 (en) 2017-05-23 2018-11-29 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US11660270B2 (en) 2017-07-20 2023-05-30 Indiana University Research And Technology Corporation Nanoparticle compositions
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
EP3717032B1 (en) 2017-11-29 2023-02-15 Ramot at Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
AU2019301316A1 (en) 2018-07-11 2021-02-18 Kahr Medical Ltd. Sirpalpha-4-1BBL variant fusion protein and methods of use thereof
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
EP3997114A1 (en) 2019-07-11 2022-05-18 KAHR Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CA3170374A1 (en) 2020-02-09 2021-08-12 Nlc Pharma Ltd Rapid detection test for sars-cov-2
WO2021176457A1 (en) 2020-03-05 2021-09-10 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
WO2021186431A1 (en) 2020-03-16 2021-09-23 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4217370A2 (en) 2020-09-23 2023-08-02 Yeda Research and Development Co. Ltd Methods and compositions for treating coronaviral infections
US20230416707A1 (en) 2020-10-07 2023-12-28 Protalix Ltd. Long-acting dnase
US20240002814A1 (en) 2020-11-03 2024-01-04 Protalix Ltd. Modified uricase and uses thereof
IL305315A (en) 2021-02-18 2023-10-01 Yeda res & development co ltd Methods for producing vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0747817B1 (en) 1995-06-07 2003-09-03 Compaq Computer Corporation Method and apparatus for controlling data communication flow in a fault-tolerant multiprocessor system
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
AU723728B2 (en) * 1996-08-02 2000-09-07 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis

Also Published As

Publication number Publication date
US20020132973A1 (en) 2002-09-19
AP9901686A0 (en) 1999-12-31
WO1998051324A1 (en) 1998-11-19
SK151599A3 (en) 2000-09-12
NO995568D0 (no) 1999-11-12
EA199901025A1 (ru) 2000-06-26
OA11216A (en) 2003-07-10
IL132901A0 (en) 2001-03-19
HUP0003349A2 (hu) 2001-01-29
HUP0003349A3 (en) 2001-12-28
CN1261281A (zh) 2000-07-26
PL336803A1 (en) 2000-07-17
BG103957A (bg) 2000-04-28
US6472505B1 (en) 2002-10-29
EP0986395A4 (en) 2004-12-01
AU7386798A (en) 1998-12-08
EA002819B1 (ru) 2002-10-31
JP2001517957A (ja) 2001-10-09
NO995568L (no) 1999-12-29
CA2290443A1 (en) 1998-11-19
UA62967C2 (en) 2004-01-15
AU746461B2 (en) 2002-05-02
EP0986395A1 (en) 2000-03-22
BR9808786A (pt) 2000-07-11
KR100351213B1 (ko) 2002-09-05
ZA984077B (en) 1998-11-24

Similar Documents

Publication Publication Date Title
KR20010012568A (ko) 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물
IL130794A0 (en) Analogs of parathyroid hormone
HUP9901718A3 (en) Analogs of parathyroid hormone
PL330869A1 (en) Non-aqueous protical peptide preparations
HUP9901455A3 (en) Somatostatin peptides
AU4844893A (en) Peptide sequencing using mass spectrometry
AU6868398A (en) Mu-opiate receptor peptides
HUP9802603A3 (en) Lipophilic peptide hormone derivatives
AU8687798A (en) Cyclic peptide antifungal agents
GB9827348D0 (en) Natriuretic peptide
AU3236297A (en) Method for the synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide
EP0996458A4 (en) SANDRAMYCIN ANALOG
AU4281999A (en) Peptide
IL132454A0 (en) Calcitonin receptor-binding peptides
AU6881998A (en) Single-chain double-alpha peptide
GB9718110D0 (en) Peptides
AU6596096A (en) Calcitonin gene-related peptide receptor component factor (houdc44)
AU6820898A (en) Natriuretic peptide derivatives
AU1999999A (en) Contryphan peptides
GB9700154D0 (en) Peptides
EP0996457A4 (en) PEPTIDES RELEASERS OF F.S.H.
GB9506372D0 (en) New peptide compounds
AU9503598A (en) Therapeutically effective 1alpha, 25-dihydroxyvitamin D3 analogs
ZA9861B (en) Analogs of parathyroid hormone
ZA978590B (en) Antibodies against human parathyroid hormone related peptide.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060816

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee